Pharma Major Dr Reddy'S Laboratories On Monday Said It Has Launched Generic Fulvestrant Injection, Used For The Treatment Of Advanced Breast Cancer, In The Us Market. The Company Has Launched Fulvestrant Injection, 250 Mg/5 Ml (50 Mg/Ml) Per Single-Dose Syringe, Approved By The United States Food And Drug Administration (Usfda), Dr Reddy'S Laboratories Said In A Filing To Bse.The Product Is A Generic Version Of Faslodex Injection In The Same Strength, It Added.According To The Iqvia Health Data, Faslodex Brand And Generic Market Had Us Sales Of Around Usd 407 Million Mat For 12 Months To June 2020, The Filing Said.
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!